VIDI SYMPOSIUM Criteria Influencing Potential Impact of HIV Prevention Interventions January 14, 2008 Thomas Fleming, PhD University of Washington Fred.

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent and Motivators.
Strategies and Interventions for Community-Based Organizations Implementing HIV Prevention Joseph Prejean, Ph. D. Capacity Building Branch Division of.
STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
Issues Associated with Acceptability of Viral STD Vaccines Susan L. Rosenthal, Ph.D.
Syphilis Trends in the United States James D. Heffelfinger, MD, MPH Epidemiology and Surveillance Branch, DSTD Centers for Disease Control and Prevention.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Measures of Impact Dublin June Measures of Impact You want to reduce deaths from road traffic accidents Most impact for least cost Cohort study.
HIV Modelling & Economics Estimating the potential impact and efficiency of PrEP for FSWs and MSM in Bangalore, southern India K.M. Mitchell 1, H.J. Prudden.
Calculate Population Attributable Risk Percent Smoke YesNo Yes No I SM = 84 / 3000 = = 28.0 / 1000 I NS = 87 / 5000 =
Male circumcision and risk of HIV infection: Current epidemiological data Helen Weiss London School of Hygiene & Tropical Medicine, UK.
The NIMH Healthy Living Project Rotheram-Borus MJ, Kelly JA, Ehrhardt AA, Chesney MA, Lightfoot M, Weinhardt LS, Kirshenbaum SB, Johnson MO, Remien RH,
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
Global Health Program Guiding Principles April 2002.
1 HIV/STD Trends in Texas Sharon K. Melville, M.D., M.P.H. Texas Department of State Health Services Texas Public Health Association April 22, 2010.
African Americans and HIV: CA Office of AIDS Response Michelle Roland, MD Chief, Office of AIDS California Department of Public Health.
HIV/STD Epidemiology in Oklahoma HIV/STD Service Division of Prevention and Preparedness Oklahoma State Department of Health.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
HIV Prevention In The Workplace Stephen Bridges National AIDS Fund April 16, 2004 New Intervention Directions CAPS Conference.
Introduction to Impact Evaluation: What is it and why do we use it? Male Circumcision Impact Evaluation Meeting Johannesburg, South Africa January 18-23,
Overview of Structural Interventions HIV Research Catalyst Forum Jennifer Hecht
Centers for Disease Control and Prevention CDC Half-Year of Diagnosis** Number of Cases **Adjusted for reporting delay AIDS Cases in Racial/Ethnic Minorities*
EPID Introduction to Analysis and Interpretation of HIV/STD Data Introduction: STDs and HIV—a brief background Manya Magnus, Ph.D. Summer 2001.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
AIDS IN ASIA – PRIORITIZING AND SUSTAINING THE RESPONSE IN THE ECONOMIC CRISIS Hanoi September 2009 ADB Consultant Ross McLeod.
November 2012 Prepared for the Contra Costa Board of Supervisors by Contra Costa Health Department Needle Exchange Update.
1 Case Studies in Prevention Trial Design Deborah Donnell, PhD SCHARP Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research Center.
STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.
Resource Needs Model Rachel Sanders October 28 th, 2010.
2008 Minnesota HIV/AIDS Surveillance Report - Key Trends Lorraine Teel- Executive Director.
Epidemiology Applications Fran C. Wheeler, Ph.D School of Public Health University of South Carolina Columbia, SC (803)
TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.
Kevin Fenton, MD, PhD National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention August 5, 2008 Update on the US HIV/AIDS Crisis: Current Trends,
New vaccines mean new strategies: A theoretical exploration of the impact of HPV/HSV vaccines. Geoff Garnett Department of Infectious Disease Epidemiology,
Topical Microbicides Antiviral Drugs Advisory Committee August 20, 2003.
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
STATE OF THE STATE SHELLEY LUCAS HIV/STD PREVENTION & CARE BRANCH DEPT OF STATE HEALTH SERVICES AUGUST 3, 2015.
Historical Mapping of HIV Programmes 1985 – 2012 in Malawi Presented at the 20 TH INTERNATIONAL AIDS CONFERENCE, MELBOURNE, AUSTRALIA 24 th July 2014 By.
Ethics in a new era Microbicides 2012 Preconference Bridget Haire.
1 Where have we failed? Findings of the Commission on AIDS in Asia Tim Brown East-West Center Modes of Transmission in the Philippines Stakeholders’ meeting.
HIM HEALTH A Social Franchise for Key Affected Populations in low to middle income countries.
Some Design Issues in Microbicide Trials August 20, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington FDA Antiviral.
1 HIV/STD in Texas Ann Robbins Texas Department of State Health Services June 2009.
ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Allie Lyman.  Incidence and Prevalence  Risk Factors and Barriers to Prevention  Prevention  Conclusion.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
4 th AMTP UA Progress Report 5 th AMTP Outcomes Framework VISION The spread of HIV is halted in the Philippines OUTCOMES Persons at-risk, vulnerable,
HIV Epidemic in Malaysia. HIV BY AGE GROUPS - MALAYSIA.
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities
HPTN Modelling Centre symposium “Recent advances in mathematical modelling to inform HIV prevention research activities and directions” IAS 2017 in.
Needle Exchange Update
A brief, trauma-informed intervention is feasible and acceptable, increases safety behaviour, and reduces HIV risk among drug-involved women who trade.
The analysis and advocacy (A2) project: Role in translating Thailand’s national AIDS strategy into provincial implementation plans S. Pantuwatana1, S.
American Public Health Association Annual Meeting
Co-infection of STIs with HIV among men who have sex with men (MSM) in Beijing, China Xiaoyan Zhang State Key Laboratory for Infectious Disease Prevention.
HIV Prevention Data Amanda Dennison, MPH Ohio Department of Health
HIV and the ART of Prevention
Tearing Down Fences HIV/STD Prevention in Rural America
Vaccine and Infectious Disease Institute
Illinois Department of Public Health
Behavioral Activation Integrated with Sexual Risk Reduction Counseling for High-Risk MSM with Crystal Methamphetamine.
PrEP.
Dianne Rausch, Ph.D. Director, Division of AIDS Research
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

VIDI SYMPOSIUM Criteria Influencing Potential Impact of HIV Prevention Interventions January 14, 2008 Thomas Fleming, PhD University of Washington Fred Hutchinson Cancer Center

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

~ 27% : Black/Hispanic MSM ~ 16% : Black/Hispanic Non-MSM → 7% heterosexual ; 9% IDU ~ 24% : White MSM ~ 3% : White Non-MSM Men → 1% heterosexual ; 2% IDU ~ 19% : Black/Hispanic Women (Heterosexual) ~ 5% : Black/Hispanic Women (Non-Heterosex) → IDU ~ 4% : White Women (Heterosexual) ~ 2% : White Women (Non-Heterosexual) Size of the Risk Groups Fraction of the US Incidence

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

Hypothetical Example ↓ in Substance Use in MSM 1. % of Tx risk addressed 11.25K (25% US incidence) ~ Size of risk group ~ 22.5K MSM ~ Attributable risk ~ 50% of MSM Tx ~ ↓ in secondary tx ( + ) 2.Plausible ↓ in RR 4.5K (10% US incidence) ~ Established POC? ~ Expect 40% ↓ in risk ~ ↓ in secondary tx ( ─ ) 3. Feasible coverage 2.25K (5% US Incidence) ~ Practical, Affordable? ~ Expect 50% coverage Criteria Influencing Potential Impact of HIV Prevention Interventions

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

Hypothetical Example ↓ in Substance Use in MSM 1. % of Tx risk addressed 11.25K (25% US incidence) ~ Size of risk group ~ 22.5K MSM ~ Attributable risk ~ 50% of MSM Tx ~ ↓ in secondary tx ( + ) 2.Plausible ↓ in RR 4.5K (10% US incidence) ~ Established POC? ~ Expect 40% ↓ in risk ~ ↓ in secondary tx ( ─ ) 3. Feasible coverage 2.25K (5% US Incidence) ~ Practical, Affordable? ~ Expect 50% coverage Criteria Influencing Potential Impact of HIV Prevention Interventions

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

Hypothetical Example ↓ in Substance Use in MSM 1. % of Tx risk addressed 11.25K (25% US incidence) ~ Size of risk group ~ 22.5K MSM ~ Attributable risk ~ 50% of MSM Tx ~ ↓ in secondary tx ( + ) 2.Plausible ↓ in RR 4.5K (10% US incidence) ~ Established POC? ~ Expect 40% ↓ in risk ~ ↓ in secondary tx ( ─ ) 3. Feasible coverage 2.25K (5% US Incidence) ~ Practical, Affordable? ~ Expect 50% coverage Criteria Influencing Potential Impact of HIV Prevention Interventions

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

Hypothetical Example ↓ in Substance Use in MSM 1. % of Tx risk addressed 11.25K (25% US incidence) ~ Size of risk group ~ 22.5K MSM ~ Attributable risk ~ 50% of MSM Tx ~ ↓ in secondary tx ( + ) 2.Plausible ↓ in RR 4.5K (10% US incidence) ~ Established POC? ~ Expect 40% ↓ in risk ~ ↓ in secondary tx ( ─ ) 3. Feasible coverage 2.25K (5% US Incidence) ~ Practical, Affordable? ~ Expect 50% coverage Criteria Influencing Potential Impact of HIV Prevention Interventions

Illustrations Vaccine MCT ART 012, , 060, Voice 1. % of Tx risk addressed ~ Size of risk group ~ Attributable risk ~ ↓ in secondary tx (+/─) ( ─ ) (+/─) 2.Efficacy of intervention ~ Established POC? ? ++ ? ~ ↓ in secondary tx ( ? ) ( ─ ) ( ? ) 3. Feasible coverage ~ Practical, Affordable? + +/─ + Criteria Influencing Potential Impact of HIV Prevention Interventions

~ 27% : Black/Hispanic MSM ~ 16% : Black/Hispanic Non-MSM → 7% heterosexual ; 9% IDU ~ 24% : White MSM ~ 3% : White Non-MSM Men → 1% heterosexual ; 2% IDU ~ 19% : Black/Hispanic Women: Heterosexual ~ 5% : Black/Hispanic Women: IDU ~ 4% : White Women: Heterosexual ~ 2% : White Women: IDU Size of the Risk Groups Fraction of the US Incidence

1.Percent of HIV transmission risk being addressed ~ Size of the risk group: fraction of the incidence ~ Attributable risk of transmission pathway addressed ~ Potential for reduction in secondary transmission 2.Intervention: Plausible Reduction in Relative Risk ~ Strength of “proof of concept” data ~ Likelihood for effect on secondary transmission 3. Feasible level of coverage of the target population ~ Affordability, Acceptability, Practicality Criteria Influencing Potential Impact of HIV Prevention Interventions

VIDI SYMPOSIUM The Way Forward for HIV Prevention: Combination Strategies (HAARP) Domestic & International Vaccines Microbicides ART MCT STD IDU Behavioral